Anixa Biosciences reports Q3 net loss, no revenue
Anixa Biosciences reported a third-quarter 2026 net loss attributable to common shareholders of $(2.61M) and diluted loss per share of $(0.08). Revenue was $0, and the company said it continued development work on oncology vaccine programs.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.